| Literature DB >> 28052023 |
Sébastien Corbineau1,2,3,4, Bruno Lassalle1,2,3,4, Maelle Givelet1,2,3,4,5,6,7, Inès Souissi-Sarahoui2,3,4,8, Virginie Firlej1,2,3,4, Paul Henri Romeo1,2,3,4, Isabelle Allemand9, Lydia Riou1,2,3,4, Pierre Fouchet1,2,3,4.
Abstract
The male germinal lineage, which is defined as unipotent, produces sperm through spermatogenesis. However, embryonic primordial germ cells and postnatal spermatogonial stem cells (SSCs) can change their fate and convert to pluripotency in culture when they are not controlled by the testicular microenvironment. The mechanisms underlying these reprogramming processes are poorly understood. Testicular germ cell tumors, including teratoma, share some molecular characteristics with pluripotent cells, suggesting that cancer could result from an abnormal differentiation of primordial germ cells or from an abnormal conversion of SCCs to pluripotency in the testis. Here, we investigated whether the somatic reprogramming factors Oct3/4, Sox2, Klf4 and c-Myc (OSKM) could play a role in SSCs reprogramming and induce pluripotency using a doxycycline-inducible transgenic Col1a1-4F2A-OSKM mouse model. We showed that, in contrast to somatic cells, SSCs from adult mice are resistant to this reprogramming strategy, even in combination with small molecules, hypoxia, or p53 deficiency, which were previously described to favour the conversion of somatic cells to pluripotency. This finding suggests that adult SSCs have developed specific mechanisms to repress reprogramming by OSKM factors, contributing to circumvent testicular cancer initiation events.Entities:
Keywords: germinal; pluripotency; reprogramming; stem cell; testis
Mesh:
Substances:
Year: 2017 PMID: 28052023 PMCID: PMC5354640 DOI: 10.18632/oncotarget.14327
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Reprogramming factors that induce pluripotency are expressed in spermatogonial progenitors except Nanog
a. Klf4, c-Myc, Lin-28, Oct4, Sox2, and Nanog expression measured by flow cytometry in cultured SSCs and b. in vivo in PLZF+ undifferentiated spermatogonia. Red, negative IgG control; blue, cells of interest. Quadrants were placed according to IgG controls. c. Expression of reprogramming factors in cultured SSCs compared with MEFs and mouse embryonic stem cells (ESCs) by quantitative RT-PCR. The expression levels of SSCs and ESCs are normalized to that of MEFs. Error bars represent SEM, n=3. * P< 0.05, ** P< 0.01, *** P< 0.001.
Figure 2Effects of the overexpression of reprogramming factors after doxycycline induction
a. Diagram of the single doxycycline-inducible polycistronic transgene in the Col1a1 locus, which drives the expression of the four mouse reprogramming factors (OSKM, encoding Oct4, Sox2, Klf4 and c-Myc) and b. the establishment of a long-term culture of SSCs from α-6+/c-Kit-/low testicular cells of Col1a1-4F2A-OSKM mice. c. Expression of the transgene (E2A-c-Myc, end part of the insert) in established SSCs cultures from Col1a1-4F2A-OSKM SSCs after 2 days of DOX induction (normalized to uninduced SSCs culture, n=3). *** P<0.001. d. Protocol used for cell reprogramming. e. Sorting strategy of testicular cell populations: spermatogonial populations of SP/α6+/c-Kit-/low and SP/ α6+/c-Kit+ progenitors and the spermatocyte I (4N) population. f. Bright-field microscopy showing representative pluripotent colonies obtained after induction using reprogramming factors in a SP/ α6+/c-Kit+ sorted population, and the reprogramming efficiency of the different cell populations tested.
Figure 3Pluripotency of reprogrammed colonies obtained from SP α6+/c-Kit+ cells
a. Alkaline phosphatase activity in colonies with an ESC-like morphology analyzed by immunocytochemistry. b. Sox2 and c. Nanog expression in ESC-like colonies by immunofluorescence. Dapi (blue) nuclear staining. d. Cells from the reprogrammed colonies co-express Oct3/4 and Sox2 as shown by flow cytometry analysis. e. Teratomas were generated in testis of NSG mice after transplantation of ESCs as a control (left) or with iPSCs from SP α6+/c-Kit+ reprogrammed colonies (right). f. Representative images of sections of teratoma obtained from iPSCs and stained with haematoxylin and eosin showing tissues derived from the three germ layers.
Figure 4The pluripotent colonies obtained from the SP/α6+/c-Kit+ population originate from contaminating somatic cells
a. Residual contamination by somatic cells occur in the sorted spermatogonial fractions. SP+/α6+/c-Kit-/low and SP/α6+/c-Kit+ populations were discriminated according to β2-microglobulin (β2m), a somatic marker. b. α6+/c-Kit+ and α6+/c-Kit-/low cell populations discriminated according to β–2 microglobulin. c. Reprogramming efficiency of the different sorted cell populations α6+/c-Kit+/β2m-, α6+/c-Kit+/β2m+, α6+/c-Kit-/low/β2m-, and α6+/c-Kit-/low/β2m+, and bright-field microscopy showing representative images of reprogrammed colonies obtained from the α6+/c-Kit+/β2m+ cell population. d. The addition of small molecules does not improve the reprogramming efficiency of sorted germinal cells from transgenic Col1a1-4F2A-OSKM mice. VPA: Valproic acid, 5-AZA: 5-Azacytidine, TSA: Trichostatin A.
Figure 5SSCs cultures are not prone to reprogramming even in the presence of small molecules or when p53 activity is diminished
a. The addition of small molecules does not increase reprogramming efficiency. b. Sorting of GFP+ cells (quadrants placed according to untransduced cells) and representative images of the culture of Col1a1-4F2A-OSKM-shRNAp53 SSCs obtained after the transduction of Col1a1-4F2A-OSKM SSCs with p53 shRNA-GFP vector (or luciferase shRNA – GFP vector as a control). c. Quantitative RT-PCR and Western blot showed a decrease in p53 expression in Col1a1-4F2A-OSKM shRNA p53 SSCs. β-actin was used as a loading control for the Western blots. Error bars represent SEM, n=3. *** P<0.001. d. Efficiency of Col1a1-4F2A-OSKM shRNA p53 reprogramming of SSCs using DOX alone or in combination with 5-AZA (2 μM), decitabine (2 μM) or hypoxia.
| Molecule | Company | Final concentration |
|---|---|---|
| Valproic Acid (VPA) | Sigma Aldrich | 2 mM |
| 5-azacytidine (5-AZA) | Sigma Aldrich | 2 μM |
| Stemolecule™ PD0325901 (2i) | Stemgent | 0.5 μM |
| Stemolecule™ CHIR99021 (2i) | Stemgent | 3 μM |
| A83-01 | Stemgent | 0.25 μM |
| Trichostatin A (TSA) | Sigma Aldrich | 20 nM |
| Cyclic pifithrin α (cPFT α) | Sigma Aldrich | 30 nM |
| Decitabine (DEC) | Tocris | 2 μM |
| Gene | Primer | Sequence or Ref. |
|---|---|---|
| GAPDH | R | 5′-CCCTTTTGGCTCCACCCT-3′ |
| F | 5′-TTCACCACCATGGAGAAGGC-3′ | |
| HPRT | R | 5′-AAAGGAAATCCAGTGGCGC-3′ |
| F | 5′-GGCTGGAGATGTTGAGAGCAA-3′ | |
| oct-04 | R | 5′-AGAACCATACTCGAACCATCC-3′ |
| F | 5′-ACATCGCCAATCAGCTTGG-3′ | |
| SOX2 | R | 5′-TGGAGTTGTACTGCAGGGCG-3′ |
| F | 5′-ACAGATGCAACCGATGCACC-3′ | |
| KLF4 | R | 5′-CCGTCCCAGTCACAGTGGTAA-3′ |
| F | 5′-GCACACCTGCGAACTCACAC-3′ | |
| c-MYC | R | 5′-TGCCTCTTCTCCACAGACACC-3′ |
| F | 5′-ACCACCAGCAGCGACTCTGA-3′ | |
| E2A-c-MYC | R | 5′-AAAGGAAATCCAGTGGCGT-3′ |
| F | 5′-GGCTGGAGATGTTGAGAGCAA-3′ | |
| PLZF | R | 5′-TTCCCACACAGCAGACAGAAG-3′ |
| F | 5′-CCCAGTTCTCAAAGGAGGARG-3′ | |
| NANOS2 | R | 5′-CCCCTTCAGGGGTCTTCA-3′ |
| F | 5′-GCAACTTCTGCAAGCACAATG-3′ | |
| CYP11A1 | R | 5′-TGCTGGCTTTGAGGAGTGGAACC-3′ |
| F | 5′-AGGGGTGGACACGACCTCCA-3′ | |
| CYP17A1 | R | 5′-GGTCTGTATGGTAGTCAGTATCG-3′ |
| F | 5′-CCAGATGGTGACTCTAGGCCTCTTGTC-3′ | |
| αSMA | R | 5′-GGAGCCACCGATCCAG-3′ |
| F | 5′-AACGCTTCCGCTGCCC-3′ | |
| VASA | R | 5′-GAAGGATCGTCTGTCTGAACA-3′ |
| F | 5′-GAAGAAATCCAGAGGTTGGC-3′ | |
| STRA8 | R | 5′-CTAAGCTGTTGGGATTCCCATC-3′ |
| F | 5′-TGAAGCTCAAAGCATCCTTCAA-3′ | |
| AMH | R | 5′-ACGGTTAGCACCAAATAGCGG-3′ |
| F | 5′-TTGCTGAAGTTCCAAGAGCCTC-3′ | |
| HSD3B | R | 5′-GGCACACTTGCTTGAACACAG-3′ |
| F | 5′-TGCACAAAGTATTCCGACCAGA-3′ | |
| STAR | R | 5′-GCGGTCCACAAGTTCTTCAT-3′ |
| F | 5′-GAAAGCCAGCAGGAGAACG-3′ | |
| LHCGR | R | 5′-CAGGGATTGAAAGCATCTGG-3′ |
| F | 5′-GAGACGCTTTATTCTGCCATCT-3′ | |
| β-actin | QuantumRNA™ β-Actin Internal Standards AM1720 (primers and probe, Life Technologies) | |
| TRP53 | Mm01731287_m1 (primers and probe, Life Technologies) | |